Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia

Donor lymphocyte infusion (DLI) is commonly used to treat leukemia relapse following stem cell transplantation. In florid relapse, however, the efficacy of DLI is limited with substantial risk of severe graft-versus-host disease (GvHD). Here, we develop a novel risk-adapted strategy characterized by...

Descripción completa

Detalles Bibliográficos
Autores principales: Rujkijyanont, P, Morris, C, Kang, G, Gan, K, Hartford, C, Triplett, B, Dallas, M, Srinivasan, A, Shook, D, Pillai, A, Pui, C-H, Leung, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763390/
https://www.ncbi.nlm.nih.gov/pubmed/23995046
http://dx.doi.org/10.1038/bcj.2013.39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763390/
https://www.ncbi.nlm.nih.gov/pubmed/23995046
http://dx.doi.org/10.1038/bcj.2013.39

Ejemplares similares